There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTO – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments.
Aptose Biosciences (APTO)
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aptose Biosciences today and set a price target of $14.00. The company’s shares closed last Tuesday at $5.49.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 49.6% and a 51.1% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $11.14.
Arcutis Biotherapeutics (ARQT)
JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Arcutis Biotherapeutics today. The company’s shares closed last Tuesday at $33.23.
According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -1.6% and a 35.7% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Aldeyra Therapeutics, and Ocuphire Pharma.
Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $51.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.